XNASLEXX
Market cap37mUSD
Dec 24, Last price
2.16USD
1D
-1.79%
1Q
-30.75%
Jan 2017
-76.77%
IPO
-59.99%
Name
Lexaria Bioscience Corp
Chart & Performance
Profile
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑08 | 2023‑08 | 2022‑08 | 2021‑08 | 2020‑08 | 2019‑08 | 2018‑08 | 2017‑08 | 2016‑08 | 2015‑08 | |
Income | ||||||||||
Revenues | 464 105.24% | 226 -11.43% | 255 -64.66% | |||||||
Cost of revenue | 6,217 | 6,760 | 7,639 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (5,753) | (6,534) | (7,384) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (114) | |||||||||
Tax Rate | ||||||||||
NOPAT | (5,753) | (6,534) | (7,269) | |||||||
Net income | (5,795) -13.05% | (6,665) -8.31% | (7,269) 190.27% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 4,209 | 1,590 | ||||||||
BB yield | -8.69% | -22.89% | ||||||||
Debt | ||||||||||
Debt current | 28 | 28 | 43 | |||||||
Long-term debt | 247 | 300 | 57 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (6,281) | (1,150) | (6,061) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (4,959) | (5,881) | (4,879) | |||||||
CAPEX | (34) | (131) | ||||||||
Cash from investing activities | (189) | (170) | (181) | |||||||
Cash from financing activities | 10,315 | 1,590 | (45) | |||||||
FCF | (5,504) | (6,419) | (7,258) | |||||||
Balance | ||||||||||
Cash | 6,556 | 1,478 | 6,161 | |||||||
Long term investments | ||||||||||
Excess cash | 6,532 | 1,466 | 6,148 | |||||||
Stockholders' equity | (51,956) | (46,119) | (39,409) | |||||||
Invested Capital | 59,752 | 48,963 | 47,060 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 12,384 | 6,614 | 5,885 | |||||||
Price | 3.91 272.42% | 1.05 -64.53% | 2.96 -52.41% | |||||||
Market cap | 48,421 597.30% | 6,944 -60.14% | 17,420 -36.22% | |||||||
EV | 41,763 | 5,430 | 11,043 | |||||||
EBITDA | (5,677) | (6,389) | (7,242) | |||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT |